MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE

Cécile Gaujoux-Viala, Christophe Hudry, Elena Zinovieva, Hélène Herman-Demars and René-Marc Flipo

Abstract

Objectives. The STRATEGE (Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis) study aimed to describe treatment strategies in current practice in RA biologic DMARD (bDMARD)-naïve patients with an inadequate response to MTX therapy, and to compare clinical efficacy of the different therapeutic strategies on disease activity after 6 months.

Methods. The main inclusion criteria of this prospective, observational, multicentre study were confirmed RA diagnosis, treatment by MTX monotherapy and need for therapeutic management modification.

Results. The 722 patients included had a mean (s.d.) RA duration of 5.3 (6.7) years, a mean DAS28 of 4.0 (1.1); they were all receiving MTX monotherapy, 68% oral, at a mean dose of 15.0 (4.1) mg/week. Two major strategies were identified: (i) MTX monotherapy dose and/or route optimization (72%) and (ii) bDMARD initiation (16%). MTX dosing was modified for 70% of patients, maintained (dose and route) for 28% of patients and interrupted for 2%. bDMARDs were started when the MTX mean dose was 17.4 mg/week, 56% parenterally; MTX was maintained concomitantly for 96% of patients. Six-month follow-up results adjusted by propensity score showed that both options were equally successful in improving disease activity and physical function, with 63 and 68% of good-to-moderate EULAR responses, respectively.

Conclusion. The STRATEGE study shows the importance of initial MTX treatment optimization before initiation of a biological treatment and emphasizes the importance of treat-to-target strategy.

Trial registration. ClinicalTrials.gov NCT02288520.

Key words: rheumatoid arthritis, methotrexate, optimization, treat-to-target, management

Introduction

MTX is considered the ‘gold standard’ of RA treatment and must be initiated in monotherapy, when there is no contraindication, immediately upon diagnosis of RA [1–3]. Guidelines recommend starting MTX at a dose of at least 10 mg/week orally and escalating in 5 mg/month increments to reach 25–30 mg/week, or the highest tolerable dose, with a subsequent switch to s.c. administration in cases of inadequate response [1–3]. However, these guidelines are not always followed, and considerable...
heterogeneity exists in prescription behaviour regarding MTX monotherapy optimization [4–7].

In addition, the guidelines only allow addition of biologic DMARDs (bDMARDs) or other conventional synthetic DMARDs (csDMARDs) to MTX treatment when monotherapy has been fully optimized (dose and route). However, evidence is scarce concerning MTX optimization in treating RA and the effect of this optimization in daily practice.

The objectives of this large nationwide observational prospective study, STRATEGE (Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis), were to describe treatment strategies in current practice in RA bDMARD-naïve patients with an inadequate response to MTX therapy, and to compare clinical efficacy of these different therapeutic strategies on disease activity after 6 months.

Methods

Study design, ethics and data access

STRATEGE was a prospective non-interventional multicentre study conducted in France, registered under the number NCT02288520 in ClinicalTrials.gov [8]. The therapeutic strategy is thus not assigned by the study protocol but falls within current practice. The study was conducted in accordance with legal and regulatory requirements. The protocol was approved by the French Data Protection Authority (CNIL; Approval number 914489) and its Advisory Committee on Information Processing in Research in the Field of Health (CCTIRS). Written informed patient consent was not required. For more information, please see supplementary Data S1, available at Rheumatology online.

The data used in this study correspond to deidentified participant data—i.e. pseudonymized—from a dataset stored and owned by Nordic Pharma; no directly nominative data was collected. According to French law, the dataset can only be shared through a controlled access; the reuse of these health data at the individual level would require an agreement with Nordic Pharma (helene.herman-demars@nordicpharma.com), and application to the French Health Data Hub (https://www.health-data-hub.fr/), with examination by the committee of experts (CESREES, Ethics and Scientific Committee for Research, Studies and Evaluations in the field of Health) and the French National Commission for Data Protection (CNIL). The French Data Protection Act and the Public Health Code restrict access to research of public interest.

Inclusion/exclusion criteria

To be eligible for STRATEGE, patients had to (i) be aged ≥18 years; (ii) have a physician diagnosis of RA satisfying ACR 1987 and/or ACR/EULAR 2010 criteria [9, 10]; (iii) be treated by MTX monotherapy; and (iv) have a clinical, functional, structural and/or therapeutic evolution requiring a treatment modification. Patients were not eligible if they had current or previous exposure to a bDMARD for their RA treatment, if they objected to their data being collected or if they were participating in a clinical study in rheumatology.

Data collection

Data were collected on paper forms at two time points: (i) at the initial visit and (ii) ~6 months later at a follow-up visit, in accordance with the practice of each centre. Baseline data included sociodemographic patient characteristics, RA history, family background and comorbidities, previous treatments, current situation description, DAS28, physical function [HAQ Disability Index (HAQ-DI)], extra-articular and radiographic features and current treatment modalities, MTX dose and route, CS, folic acid, etc. The patient’s options of disease management and the chosen new treatment (features and reasons) were reported.

Six-month follow-up data considered the impact of the chosen strategy on disease and treatment features, any therapeutic modifications and any adverse events (AEs).

In case of missing data, the physician was contacted to retrieve the missing information as much as reasonably possible. Missing values were not imputed.

Outcomes

To describe treatment strategies in RA patients with inadequate response to MTX therapy, we considered MTX prescription characteristics, reasons for treatment modification and the modalities of other csDMARDs and bDMARDs prescriptions. Patient characteristics at inclusion are described for the overall population and in each therapeutic strategy identified. MTX features are also described at 6 months after treatment modification.

The different strategies were compared at 6 months through efficacy outcomes assessed as change in DAS28 and HAQ-DI scores and EULAR response, and patient-reported outcomes, assessing pain (on a visual analogue scale, 0–100) and satisfaction on a four-point scale (Very satisfied, Satisfied, Unsatisfied, Very unsatisfied).

Finally, safety outcomes are presented, detailing AE related to MTX and serious AE.

Statistical analyses

Descriptive analyses are presented using frequencies and percentages for qualitative variables and means (s.d.) or medians (min–max), as appropriate, for continuous variables. Outcomes were compared between the different therapeutic strategies using analysis of covariance adjusted for baseline DAS28 and baseline HAQ-DI.

A propensity score adjustment was modelled to compare efficacy outcomes at 6 months for the two major identified therapeutic strategies. Indeed, due to the lack of randomization of the treatment optimization, patients were likely to have different clinical and demographic characteristics at the time of treatment choice,
introducing a potential indication bias. We thus estimated each patient’s propensity score, reflecting the probability of receiving one of the two compared therapeutic strategies, using a binary logistic-regression model. This model included, as explanatory variables, 22 candidate predictors available at baseline a priori possibly explaining the therapeutic strategy assigned by the clinician (supplementary Table S1 and Figure S1, available at Rheumatology online); only variables shown to be related to at least one of the health outcomes were retained in the model. The adequacy of the model was approached by the c-index (area under the receiver operating characteristic curve) and the Hosmer–Lemeshow goodness-of-fit test. The individual propensity scores were then considered as explanatory variable within the linear regression model that assessed the relation between the treatment strategies and the change in DAS28 score from baseline to 6 months, as a continuous variable.

The statistical analysis used SAS 9.4 software (SAS Institute, Cary, NC, USA).

Results

Study population

Between August 2014 and September 2015, 176 rheumatologists, 90% in private practice, recruited 854 patients, 722 of whom comprised the analysable baseline set (Fig. 1). There were very few items with missing data (Tables 1 and 2). Participants had a mean (S.D.) RA duration of 5.3 (6.7) years, and a mean DAS28 of 4.0 (1.1). Disease activity levels according to DAS28 were high for 17% patients, medium for 63%, low for 12% and remission for 8%.

Patients were all receiving MTX monotherapy at inclusion, 68% oral and 32% parenterally, 30% s.c., 2% i.m., at a mean dose of 14.9 (4.1) mg/week (Table 1 and Fig. 2). Fifty percent of patients taking MTX parenterally required assistance from a nurse or caregiver to perform their injections. MTX was the first-line csDMARD in 84% of patients, of whom 66% received it in the first 3 months after diagnosis. Prior to the initial visit, 15% of

---

**Fig. 1** Study flowchart

| 854 patients: Selection |
|-------------------------|
| • MTX in combination with cs/b DMARDs (N = 5) |
| • MTX withdrawal or decrease (N = 47) |
| • No therapeutic modification (N = 79) |
| • No data (N = 1) |

| 722 patients: Baseline analysable set |
|--------------------------------------|
| MTX mono optimization 519 |
| bDMARD ± MTX 117 |
| csDMARD combination 39 |
| Corticosteroid modification only 47 |

| 703 patients: M6 analysable set |
|---------------------------------|
| • Early withdrawal (N = 17) |
| • Incomplete M6 visit (N = 2) |

| Safety population: 829 patients |

| M6, six-months’ visit |
### Table 1 Patient baseline characteristics

| Baseline characteristics | Overall (n = 722) | Missing | Therapeutic strategy at the end of the initial visit |
|--------------------------|------------------|---------|------------------------------------------------------|
|                          |                  |         | Two main therapeutic strategies | Other therapeutic strategies |
|                          |                  |         | (1) MTX monoth. OPT (n = 519) | (2) bDMARD ± MTX (BT) (n = 117) | P-value (OPT vs BT) | (3) csDMARDs combination (n = 39) | (4) CS modification only (n = 47) |
| Demographic characteristics |                  |         |                                     |                                     |                        |                                     |                                   |
| Age, mean (s.d.), years  | 57.0 (13.7)      | 0       | 58.0 (14.0) | 52.6 (12.5) | <0.001 | 54.6 (12.9) | 58.3 (12.9) |
| Female, n (%)            | 537 (74.5)       | 1       | 377/518 (72.8) | 94/117 (80.3) | 0.091 | 28/39 (71.8) | 38/47 (80.9) |
| RA characteristics       |                  |         |                                     |                                     |                        |                                     |                                   |
| RA duration, mean (s.d.), years | 5.5 (6.7)      | 3       | 5.2 (6.5) | 6.5 (7.1) | 0.058 | 6.7 (8.6) | 4.9 (5.3) |
| RF positive, n (%)        | 521 (73.9)       | 17      | 359/505 (71.1) | 98/116 (84.5) | 0.003 | 31/38 (81.6) | 33/46 (71.7) |
| ACPA positive, n (%)      | 480 (70.1)       | 37      | 330/490 (67.3) | 91/114 (79.8) | 0.009 | 26/35 (74.3) | 33/46 (71.7) |
| Radiographic damage, n (%)| 278 (38.8)       | 5       | 187/515 (36.3) | 58/116 (50.0) | 0.006 | 17/39 (43.6) | 16/47 (34.0) |
| Extra-articular manifestations, n (%) | 74 (10.2)   | 0       | 44/519 (8.5) | 22/117 (18.8) | <0.001 | 6/39 (15.4) | 2/47 (4.3) |
| CRP, mean (s.d.), mg/l    | 12.9 (19.8)      | 34      | 12.0 (12.1) | 17.6 (39.1) | 0.134 | 11.7 (10.8) | 12.0 (19.3) |
| ESR, mean (s.d.), mm/h    | 24.5 (21.6)      | 31      | 24.4 (22.9) | 27.6 (17.8) | 0.107 | 22.4 (17.2) | 18.7 (17.1) |
| DAS28, mean (s.d.)        | 4.1 (1.1)        | 29      | 4.0 (1.0) | 4.6 (1.1) | <0.0001 | 4.3 (1.2) | 3.7 (1.2) |
| HAQ-DI, mean (s.d.)       | 1.0 (1.4)        | 108     | 0.9 (1.0) | 1.1 (1.3) | 0.074 | 1.5 (4.3) | 1.0 (1.3) |
| Pain VAS, median (Q1–Q3)  | 50 (30–60)       | 7       | 50 (30–60) | 60 (40–70) | – | 40.0 (25–65) | 40 (30–60) |
| Treatment characteristics at inclusion |                 |         |                                     |                                     |                        |                                     |                                   |
| Delay between RA diagnosis and MTX initiation, mean (s.d.), years | 1.7 (4.2)      | 5       | 1.6 (4.3) | 1.8 (4.6) | 0.653 | 2.1 (4.3) | 1.4 (3.0) |
| Delay between RA diagnosis and MTX initiation, n (%) | 0              |         |                                     |                                     |                        |                                     |                                   |
| ≤3 months                | 479 (66.3)       | 35      | 351/519 (67.6) | 80/117 (68.4) | 0.876 | 17/39 (43.6) | 31/47 (66.0) |
| >3 months                | 243 (33.7)       | 108     | 168/519 (32.4) | 37/117 (31.6) | 0.0001 | 22/38 (56.4) | 16/47 (34.0) |
| MTX current dose, mean (s.d.), mg/week | 14.9 (4.1)   | 7       | 14.1 (3.9) | 17.4 (3.5) | <0.0001 | 17.5 (4.6) | 15.8 (3.9) |
| MTX current dose (classes), n (%), mg/week | 7              |         |                                     |                                     |                        |                                     |                                   |
| ≤15                      | 509/715 (71.2)   | 10      | 409/515 (79.4) | 53/116 (45.7) | 0.001 | 16/37 (43.2) | 31/47 (66.0) |
| 15–20                    | 26/715 (3.6)     | 10      | 18/515 (3.5) | 6/116 (5.2) | <0.0001 | 1/37 (2.7) | 1/47 (2.1) |
| ≥20                      | 180/715 (25.2)   | 10      | 88/151 (57.1) | 57/116 (49.1) | 0.0001 | 20/37 (54.1) | 15/47 (31.9) |
| Parenteral MTX, n (%)     | 230 (32.3)       | 10      | 130/513 (25.3) | 65/116 (56.0) | <0.0001 | 16/36 (44.4) | 19.0/47(40.4) |
| CS prescriptions, n (%)   | 377 (52.2)       | 0       | 255/519 (48.1) | 62/117 (53.0) | 0.451 | 22/38 (56.4) | 38/47 (80.9) |
| Folic acid prescriptions, n (%) | 998 (82.8) | 0       | 442/519 (85.2) | 95/117 (81.2) | 0.285 | 26/39 (66.7) | 35/47 (74.5) |

bDMARD: biological DMARDs; BT: biotherapy (i.e. bDMARD ± MTX); csDMARD: conventional synthetic DMARD; HAQ-DI: HAQ Disability Index; monoth.: monotherapy; OPT: optimization (i.e. MTX monotherapy optimization); VAS: visual analogue scale.

MTX optimization or adding bDMARD equally improve disease activity in RA.
| MTX features at the end of the initial visit | Therapeutic strategy at the end of the initial visit |
|---------------------------------------------|-----------------------------------------------------|
| MTX modified route and/or dose, n (%)       | Overall (n = 722) Missing                          |
|                                             | Two main therapeutic strategies Other therapeutic strategies |
|                                             | (1) MTX monoth. OPT (n = 519) (2) bDMARD ± MTX (BT) (n = 117) (3) csDMARDs combination (n = 39) (4) CS modification only (n = 47) |
| MTX modified route and/or dose, n (%)       | 561 (77.7) 0 519/519 (100.0) 31/117 (26.5) 11/39 (28.2) |
| MTX unchanged, n (%)                        | 146 (20.2) – 81/117 (69.2) 18/39 (46.1) 47/47 (100.0) |
| MTX interrupted, n (%)                      | 15 (2.0) – 51/117 (4.2) 10/39 (25.6) – |

### Reasons for treatment modification (more than one reason could be cited)

| MTX features at the end of the initial visit | Therapeutic strategy at the end of the initial visit |
|---------------------------------------------|-----------------------------------------------------|
| MTX modified route and/or dose, n (%)       | Overall (n = 722) Missing                          |
|                                             | Two main therapeutic strategies Other therapeutic strategies |
|                                             | (1) MTX monoth. OPT (n = 519) (2) bDMARD ± MTX (BT) (n = 117) (3) csDMARDs combination (n = 39) (4) CS modification only (n = 47) |
| Active RA (DAS28 > 3.2), n (%)              | 530 (73.4) 0 378/519 (72.8) 99/117 (84.6) 28/39 (71.8) 25/47 (53.2) |
| RA not in remission (2.6 < DAS28 < 3.2), n (%) | 73 (10.1) 0 57/519 (10.9) 4/117 (3.4) 5/39 (12.8) 7/47 (14.9) |
| Worsening of clinico-biological parameters, n (%) | 234 (32.4) 0 153/519 (29.5) 49/117 (41.9) 12/39 (30.1) 20/47 (42.5) |
| Radiographic progression, n (%)             | 107 (14.8) 0 58/519 (11.2) 46/117 (39.3) 1/39 (2.6) 2/47 (4.2) |
| CS sparing, n (%)                           | 81 (11.2) 0 59/519 (11.4) 18/117 (15.4) 3/39 (7.7) 1/47 (2.1) |
| Poor tolerance of the current treatment, n (%) | 29 (4.0) 0 16/519 (3.1) 7/117 (5.9) 5/39 (12.8) 1/47 (2.1) |
| MTX                                        | 24 (82.7) 0 13/16 (81.2) 5/7 (71.4) 5/5 (100.0) 1/1 (100.0) |
| Other medication (NSAIDs, CS, etc.)         | 4 (13.8) 0 3/16 (0.6) 0/7 (0.0) 1/5 (20.0) 0/1 (0.0) |
| Poor treatment adherence, n (%)             | 7 (0.9) 0 6/519 (1.1) 1/117 (0.8) 0/39 (0.0) 0/39 (0.0) |

*bdMARD monotherapy: tocilizumab for three patients, certolizumab for one patient, etanercept for one patient. bNew csDMARD monotherapy: LEF for 10 patients. bdMARD: biological DMARD; BT: biotherapy (i.e. bdMARD ± MTX); csDMARD: conventional synthetic DMARD; monoth.: monotherapy; OPT: optimization (i.e. MTX monotherapy optimization).
patients had MTX tapering due to gastrointestinal intolerance, liver cytolysis and other unknown reasons.

**Treatment modifications in real-life in RA patients with inadequate response to MTX therapy**

Four distinct treatment modification strategies were identified in RA patients with inadequate responses to initial MTX monotherapy: (group 1) MTX monotherapy optimization for dose and/or route (72%, n = 519); (group 2) initiation of a first bDMARD (16%, n = 117), for 96% in combination with MTX; (group 3) prescription of csDMARD(s) other than MTX (5%, n = 39), for 74% in combination with MTX; and (group 4) maintenance of MTX monotherapy (same route and dose) with only CS prescription modification (7%, n = 47; Table 1 and Fig. 1).

The main two reasons to justify treatment modification were active disease, in 73.4% of patients (n = 530), and/or worsening of clinico-biological parameters, in 32.4% of patients (n = 234). These reasons were the two most common justifications in each of the four strategy groups (Table 2). Remarkably, radiographic progression was cited in 40% of patients as a reason to initiate a first bDMARD for group 2, in comparison to 3–11% for other therapeutic strategies. In contrast, parenteral MTX was started mainly for efficacy reasons, safety being cited for only 5% of patients.

Regarding MTX treatment, the MTX mean dose was raised to 17.3 (4.0) mg/week from 14.9 (4.1) mg/week before modification, and the percentage of parenteral administration increased from 32 to 50% (Fig. 2). When either a bDMARD or csDMARDs were started, MTX prescription remained unmodified (dose and route) in 69 and 46% of cases, respectively. MTX was stopped for only 15 patients (Table 2).

The nature of bDMARDs and csDMARDs prescribed for strategy groups 2 and 3, respectively, are provided in Fig. 3.

The initiation of the first biologic therapy occurred at a mean DAS28 of 4.6 (1.1), after a mean RA duration of 6.5 (7.1) years when MTX mean dose was 17.4 (3.5) mg/week (45.7% of patients treated with a dose ≤15 mg/week, 5.2% a dose 15–20 mg/week and 49.1% a dose ≥20 mg/week), with 56% of s.c. administration and concomitant CS prescriptions for 53% of patients. At inclusion, s.c. administration was less used in group 1 (25.3%) and mean dose was 14.1 (3.9) mg/week (79.4%: ≤15 mg/week; 3.5%: 15–20 mg/week; and 17.1%: ≥20 mg/week) (Table 1).

**MTX features at the 6-month visit from treatment modification**

Over the 6-month period, MTX prescription was maintained (dose and route) for 20% of patients (n = 146), interrupted for 2% (n = 15) and modified for 78% (n = 561; Table 2). An oral-to-parenteral switch was decided for 27% of patients (n = 151). Among these 151 patients, the MTX dose remained identical for 50% [n = 76; 16.4 (3.6) mg/week], was raised for 46% [n = 69; from 13.7 (3.1) mg/week to 18.4 (3.2) mg/week] and reduced for 4% [n = 6; from 20.0 (3.2) mg/week to 15.0 (3.2) mg/week].

**Assessment and comparison of the 6-month efficacy outcomes for the different therapeutic strategies**

Significant DAS28 improvement was achieved after 6 months of treatment, regardless of the treatment strategy used (Fig. 4a). Mean DAS28 improved from ‘active disease’
to ‘low disease activity’, with the proportion of patients in remission or with low disease activity ranging from 56% to 70% for the various strategies (Fig. 4d). DAS28 comparison did not show any significant differences between the three ‘active’ strategies: (group 1) MTX monotherapy optimization, (group 2) bDMARD + MTX and (group 3) csDMARDs combination, compared with (group 4) CS modification only, considered here as a reference since no disease-modifying treatment was changed (P = 0.67, analysis of covariance).

The percentage of patients reaching a good or moderate EULAR response was 63% for group 1 MTX monotherapy optimization, 68% for group 2 bDMARD ± MTX and 67% for the other two strategies, groups 3 and 4. All the strategies were equally (P = 0.39) successful in significantly improving physical function, measured by HAQ-DI (Fig. 4b) and pain (visual analogue scale; Fig. 4c). Globally, >80% of patients declared themselves satisfied or very satisfied with their treatment strategy after 6 months.

Focus on the two main therapeutic strategies, groups 1 and 2

The two most common therapeutic strategies to be compared with propensity scores for 6-month efficacy
outcomes were (group 1) MTX monotherapy optimization for dose and/or route (72%, n = 519) and (group 2) initiation of a first bDMARD (16%, n = 117).

Sociodemographic features, unrelated to disease status, were comparable among the two treatment groups except that patients proceeding to bDMARD ± MTX were younger. They also had a more active (DAS28, CRP level), more pain and more erosive disease with higher level of RF/ACPAs positivity (Table 1). The dose of MTX was higher and parenteral route was more frequent than in MTX optimization.

Efficacy outcomes were compared after adjusting baseline characteristics through individual propensity scores. Distributions of individual propensity scores are available in supplementary Fig. S1, available at Rheumatology online. The final model for the propensity score included the following baseline variables: patient age (≥60 years old), current smoking status, ACPA and RF positivity, DAS28 and HAQ, extra-articular manifestations and radiographic damage (supplementary Table S1, available at Rheumatology online; c-index: 0.73, Hosmer–Lemeshow goodness-of-fit: P = 0.73). There was still no significant difference in DAS28 between the groups when adjusting with propensity scores (P = 0.71; regression coefficient: 0.06, 95% CI −0.26, 0.38). Similarly, no significant differences were found for any of the patient-reported outcome criteria after adjusting with propensity scores (P = 0.99 for function, 0.68 for pain and 0.327 for satisfaction).  

Safety

Of the 829 patients comprising the safety population, 23.5% reported at least one AE during the 6 months of follow-up and 10% of patients reported at least one AE related to MTX. No unexpected safety concerns were raised during the study. During the study, no unexpected serious AE was reported. Three percent of patients experienced serious AE, predominantly hepatic cytolysis, neutropenia or leucopenia. There was no difference in AE frequency in the bDMARDS group vs the MTX optimization group.

Discussion

STRATEGE is the first large, nationwide, observational study exploring therapeutic strategies in RA patients treated with MTX monotherapy, and requiring a treatment modification for clinical, functional, structural and/or therapeutic reasons. The two major strategies were (group 1) MTX monotherapy optimization (72%) and (group 2) initiation of a bDMARD (16%), generally associated with MTX. After 6 months, both strategies appeared to be equally successful in improving disease activity (DAS28), physical function, pain and patient satisfaction.

The introduction of the treat-to-target (T2T) principal, with intensive monitoring and clearly defined therapeutic strategies, has contributed to major improvements in the treatment of RA patients [11]. Over the past two decades, several studies have searched for the optimal strategy to apply in early-diagnosed RA patients [12–14]. A recently published analysis on patients selected from the Measurement of Efficacy of Treatment in the “Era of Outcome” in Rheumatology (METEOR) international registry partly addressed this question in a real-life setting [15, 16]. Patients were included after failure on MTX monotherapy and were divided into three groups: csDMARDs ± MTX, MTX + glucocorticoids and bDMARD ± MTX. Patients were followed over 1 year of maintenance treatment. After propensity score adjustment, this study showed that bDMARD ± MTX strategy was more effective than csDMARDs ± MTX or MTX + glucocorticoids in decreasing disease activity, seeming to contradict our findings. Moreover, a bDMARD-based strategy appeared to present better treatment-survival results. However, in this study, MTX monotherapy was already optimized before inclusion. The most frequent STRATEGE option, consisting of MTX monotherapy optimization by dose raising and/or parenteral administration, was not explored in the METEOR analysis.

In our real-life study, MTX monotherapy optimization showed equally effective results on DAS28 and HAQ-DI in almost three-quarters of the patients when compared with bDMARDs initiation ± MTX. Indeed, several studies have shown that MTX optimization is a valuable choice with numerous benefits, potentially avoiding or at least delaying the introduction of costly targeted therapies [17, 18]. For instance, the efficacy of MTX dose optimization was recently demonstrated in 314 RA patients from the early arthritis Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort receiving MTX as a first DMARD (53%) [mean dose 12.2 (3.8) mg/week]. Only 26.4% had optimal MTX dose (defined as initial dose ≥10 mg/week for the first 3 months, with escalation to ≥20 mg/week or 0.3 mg/kg/week at 6 months if DAS28 remission was not obtained). In this cohort, the route of MTX administration was mainly oral (96.8% of patients). After adjustment, the optimal MTX dose was significantly more effective than a non-optimal dose in reaching remission and improving function in RA patients at 1 and 2 years (ACR-EULAR remission at 1 year: odds ratio = 4.28, 95% CI 1.86, 9.86) [15].

Another way to optimize MTX is parenteral administration. S.c. MTX has shown improved clinical efficacy [19], improved bioavailability, especially at doses >15 mg/week [20], and improved treatment survival, when compared with oral MTX [21–23]. Moreover, a retrospective cohort study on >7000 patients showed that the use of s.c. MTX, compared with oral, was associated with longer duration of MTX monotherapy before addition/switching to bDMARDs [18]. Although no randomized controlled trials have yet directly compared s.c. MTX monotherapy vs targeted therapies ± MTX, several observational analyses have shown that the first option was more cost effective for patients and for society as a whole [21, 24, 25].
The second most frequently used strategy in our study was bDMARD ≥ MTX, applied to about one-sixth of patients, preferably patients with slightly higher DAS28 and pain. More of them presented with structural damage, extraarticular manifestations and were unsatisfied with their current treatment compared with patients using other strategies. Literature data are scarce on current practice regarding MTX prescription at the moment of biologic initiation. One recent US study addressed this question, analysing Symphony Health Solutions registry data from 2009 to 2014 [8]. It showed that, consistent with our results, biologics tended to be initiated while MTX was still suboptimally dosed (15.3–15.9 vs 17.4 mg/week in STRATEGE). The s.c. route was chosen in only 13–16% in patients from the Symphony Health Solutions registry vs 56% of s.c. MTX in STRATEGE at the moment of bDMARD initiation. The higher proportion of MTX optimization in our study could be because the STRATEGE study inclusions started at the end of the inclusion period of the American registry. In our study, in contrast to patients with a MTX optimization, the group who switched to bDMARD seemed to have a former history of optimization: 56 vs 25.3% of s.c. administration and higher dose level, in particular in the range of dose ≥ 20 mg/week (49.1 vs 17.1%). In these patients, MTX dose was ≤ 15 mg/week for 45.7% of them and s.c. administration was not used in 44%, therefore it is likely that further MTX optimization was possible.

Finally, we found that MTX was maintained in 96% of cases upon bDMARD initiation, with no change in dose or route in 69% of cases, in line with European and National guidelines [2, 3]. However, it remains unknown whether MTX is maintained throughout the bDMARD (and recently targeted synthetic DMARD) treatment duration.

The STRATEGE study was the first investigation of current practice treatment options and their 6-month impact on RA bDMARD-naïve patients with inadequate response to MTX initial monotherapy. It emphasized the benefit of MTX monotherapy dose/and route optimization, showing the same efficacy results as the other strategies, but being more cost effective and confirming the importance of the T2T principle. We also observed that at the moment of bDMARD initiation, MTX was still suboptimally dosed and that the s.c. route was underutilized, leaving room for improvement, potentially leading to biologic treatment sparing and/or delay.

One of the strengths of this study is that we included a wide spectrum of patients with RA. The STRATEGE study aimed to include all patients with RA with inadequate response to MTX monotherapy and bDMARD-naïve regardless of disease level, age and sex, reflecting the real-life setting. Our study has some limitations. We tried to include all baseline covariates associated with treatment assignment and/or those affecting outcome. However, some confounders may have been omitted, although propensity scoring was done to reduce selection bias between groups.

The two most common therapeutic strategies should be compared with caution. It is not possible to exclude that the study is underpowered to detect a difference between the two strategies due to the lower proportion of bDMARD patients (117 vs 519 in the MTX monotherapy optimization strategy).

However, the absolute DAS28 change difference between MTX optimization group and biologics group was 0.36 (non-significant), and the absolute HAQ change difference was 0.11 (non-significant), below the minimal clinically important difference [26]. In addition, the biologic cohort had higher baseline values so more regression to the mean is to be expected.

The results of our study provide some evidence that MTX monotherapy optimization in patients with RA in a real-life setting could be equally successful at 6 months in improving disease activity, physical function, pain and patient satisfaction as initiation of a bDMARD combined with MTX. These data suggest that efforts are needed to achieve a better use of MTX for RA (initiation during the first 3 months and with optimization). The STRATEGE study has shown an important role for MTX treatment optimization before initiation of a biological treatment and emphasizes the importance of a T2T strategy. By enhancing our knowledge of the use of MTX for RA, we will be able to optimize the use of this key drug in clinical practice and improve the well-being of our patients.

Acknowledgements

This study, including editorial assistance, was funded by Nordic Pharma France. The authors thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. The authors also acknowledge Claire Billard (GECEM) and Karine Mari (RCTS) for statistical assistance. We thank Sarah Kabani for proofreading the final version of manuscript (in-house medical writer, CHU Nîmes). C.G.-V., C.H., E.Z., H.H.-D. and R.-M.F. designed the study; C.G.-V., E.Z. and R.-M.F. interpreted the results and drafted the manuscript. All authors reviewed the manuscript and gave their approval for submission.

Funding: Nordic Pharma sponsored the study and the development of this manuscript, and reviewed the text to ensure that from Nordic Pharma’s perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of Nordic Pharma, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content.

Disclosure statement: C.G.-V. reports speaking and/or consulting fees from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck-Serono, Medac, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma. R.-M.F. reports speaking and/or consulting...
Data availability statement

The dataset can only be shared through a controlled access; the reuse of these health data at the individual level would require an agreement with Nordic Pharma (helene.herman-demars@nordicpharma.com), and application to the French Health Data Hub (https://www.health-data-hub.fr/)

Supplementary data

Supplementary data are available at Rheumatology online.

References

1. Smolen JS, Landewe RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685–99.
2. Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68:1–26.
3. Daïen C, Hua C, Gaujoux-Viala C et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 2019; 86:135–50.
4. St Clair EW, van der Heijde DMFM, Smolen JS et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432–43.
5. Westhovens R, Robles M, Ximenes AG et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68:1870–7.
6. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68:1086–93.
7. Combe B, Rincheval N. Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. Joint Bone Spine 2015; 82:13–7.
8. Nordic Pharma SAS. Therapeutic Strategy in Rheumatology When Faced With a Patient Treated With Methotrexate (MTX) for Rheumatoid Arthritis (RA). 2016. [Internet]. clinicaltrials.gov; https://clinicaltrials.gov/ct2/show/NCT02288520 (8 October 2020, date last accessed).
9. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–24.
10. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–81.
11. Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75:3–15.
12. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381–90.
13. Verstappen SMM, Jacobs JWG, van der Veen MJ et al.; Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443–9.
14. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263–9.
15. Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Ann Rheum Dis 2017; 76:2054–60.
16. Bergstra SA, Allaart CF. What is the optimal target for treat-to-target strategies in rheumatoid arthritis? Curr Opin Rheumatol 2018; 30:282–7.
17. Koduri GM, Mukhtyar C. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58:559–60.
18. Harris E, Ng B. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis. Eur J Rheumatol 2018; 5:85–91.
19. Braun J, Kästner P, Flaxenber P et al.; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58:73–81.
20. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014; 73:1549–51.
21 Scott D, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol 2014;43:470–6.

22 Hazlewood GS, Thorne JC, Pope JE et al.; CATCH Investigators. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 2016;75:1003–8.

23 Moura CS, Schieir O, Valois M-F et al.; Canadian Early Arthritis Cohort Investigators. Treatment strategies in early rheumatoid arthritis methotrexate management: results from a prospective cohort. Arthritis Care Res (Hoboken) 2020;72:1104–11.

24 Lee J, Pelkey R, Gubitosa J, Henrick MF, Ganz ML. Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States. Am Health Drug Benefits 2017;10:42–9.

25 Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol 2013;32:1605–12.

26 Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 2015;74:1691–6.